Indianapolis

INDIANAPOLIS, December 8, 2011 - - Eli Lilly and Company launching global disease awareness campaign in more than 15 countries to encourage men to talk to their doctors about erectile dysfunction (ED) An international survey sponsored by Eli Lilly and Company (NYSE: LLY) found large cultural differences between European, Asian and North American countries when it comes to men and women discussing sexual health issues with their doctors.

INDIANAPOLIS, October 28, 2011 - Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted marketing authorization for the use of ALIMTA (pemetrexed for injection) as continuation maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

INDIANAPOLIS, October 25, 2011 - Eli Lilly and Company (NYSE: LLY) announces withdrawal of its Xigris [drotrecogin alfa (activated)] product in all markets following results of the PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock.

INDIANAPOLIS, September 26, 2011 - Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA (pemetrexed for injection) as continuation maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

INDIANAPOLIS, September 13, 2011 - - The Lilly NCD Partnership will seek innovative solutions to help fight chronic diseases in developing countries Eli Lilly and Company (NYSE: LLY) announced today a $30 million commitment over five years to fight the rising burden of non-communicable diseases in developing nations.